TSNL.F Stock Overview
Develops, manufactures, and sells infection prevention products in the United Kingdom, Australia, Germany, Western Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Tristel plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£5.29 |
| 52 Week High | UK£5.29 |
| 52 Week Low | UK£5.09 |
| Beta | 0.26 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 4.13% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -11.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| TSNL.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 0.9% | 2.2% |
| 1Y | 4.1% | 21.9% | 32.6% |
Return vs Industry: TSNL.F underperformed the US Medical Equipment industry which returned 10.5% over the past year.
Return vs Market: TSNL.F underperformed the US Market which returned 25.3% over the past year.
Price Volatility
| TSNL.F volatility | |
|---|---|
| TSNL.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TSNL.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TSNL.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 208 | Paul Swinney | tristel.com |
Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. It offers medical instrument disinfection products, including airway management, cardiology, ear, nose and throat, endoscopy, gastrointestinal physiology, laboratory, ophthalmology, phlebotomy, reproductive health/IVF, surface, ultrasound, urology, women's health, and other products under the Tristel brand.
Tristel plc Fundamentals Summary
| TSNL.F fundamental statistics | |
|---|---|
| Market cap | US$289.70m |
| Earnings (TTM) | US$7.81m |
| Revenue (TTM) | US$51.12m |
37.1x
P/E Ratio5.7x
P/S RatioIs TSNL.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TSNL.F income statement (TTM) | |
|---|---|
| Revenue | UK£39.49m |
| Cost of Revenue | UK£6.91m |
| Gross Profit | UK£32.58m |
| Other Expenses | UK£26.54m |
| Earnings | UK£6.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 82.49% |
| Net Profit Margin | 15.29% |
| Debt/Equity Ratio | 0% |
How did TSNL.F perform over the long term?
See historical performance and comparison